Details for Patent: 11,661,604
✉ Email this page to a colleague
Which drugs does patent 11,661,604 protect, and when does it expire?
Patent 11,661,604 protects RIVFLOZA and is included in one NDA.
This patent has nineteen patent family members in fourteen countries.
Drugs Protected by US Patent 11,661,604
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-001 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1) | ⤷ Sign Up | ||
| Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-002 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1) | ⤷ Sign Up | ||
| Novo | RIVFLOZA | nedosiran sodium | SOLUTION;INJECTION | 215842-003 | Sep 29, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1) | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,661,604
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018346971 | ⤷ Sign Up | |||
| Canada | 3078933 | ⤷ Sign Up | |||
| China | 111448319 | ⤷ Sign Up | |||
| European Patent Office | 3679141 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
